Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats
Microcirculation · 2023
DOI: 10.1111/micc.12825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microcirculation, 2023. Verfasst von Joana Costa d'Avila und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pre-clinical Research Laboratory, Iguaçu University, Nova Iguaçu, Brazil. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Liraglutide, Microcirculation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Universidade Iguaçu.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the effects of the antidiabetics liraglutide, a GLP‐1 analog, and empagliflozin, an SGLT‐2 inhibitor, on the brain microcirculation of diabetic rats.
Methods
Type 2 diabetes mellitus (DM) was experimentally induced in male Wistar rats by combining a high‐fat diet and a low dose of streptozotocin (35 mg/kg). Liraglutide (100 μg/kg s.c.) and empagliflozin (10 mg/kg, oral) were administered for 5 weeks. Body weight was monitored periodically. Oral glucose tolerance, fasting glycemia, and blood triglycerides were evaluated after the treatments. Endothelial–leukocyte interactions in the brain microcirculation and structural capillary density were assessed.
Results
DM rats presented metabolic and cerebrovascular alterations. Liraglutide treatment decreased body weight and blood triglycerides of DM rats. Empagliflozin treatment improved glucose tolerance but only the combination therapy significantly reduced fasting blood glucose. Both treatments and their combination reduced leukocyte adhesion into the endothelium of brain venules. However, empagliflozin was more effective in preventing DM‐induced microvascular rarefaction.
Conclusion
These findings suggest that chronic treatment with SGLT2 inhibitors and GLP‐1 receptor agonists may serve as potential therapeutic approaches to prevent microvascular complications associated with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pre-clinical Research Laboratory, Iguaçu University, Nova Iguaçu, Brazil.
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.
- School of Medicine, Estácio de Sá University, Rio de Janeiro, Brazil.
ORCID-Profile: Joana Costa d'Avila
Förderung
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Universidade Iguaçu
Zitieren
APA
d'Avila, J. C., Carlos, A. S., Vieira, R. L., Vergueiro, C., Lima, A. T., Silva, I. D. S., de Figueiredo, V. C., Chateaubriand, P. H. P., Moreno, A. M., de Castro Faria Neto, H. C., Estato, V., & Siqueira, R. A. (2023). Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats. Microcirculation. https://doi.org/10.1111/micc.12825
Vancouver
d'Avila JC, Carlos AS, Vieira RL, Vergueiro C, Lima AT, Silva IDS, et al. Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats. Microcirculation. 2023. doi:10.1111/micc.12825
BibTeX
@article{dAvila2023,
author = {d'Avila, Joana Costa and Carlos, Aluana Santana and Vieira, Raimundo Lima and Vergueiro, Carla and Lima, Aline Teixeira and Silva, Isaias Dos Santos and de Figueiredo, Vivian Carvalho and Chateaubriand, Paulo Henrique Petrone and Moreno, Adalgiza Mafra and de Castro Faria Neto, Hugo Caire and Estato, Vanessa and Siqueira, Rodrigo Azeredo},
title = {Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats},
journal = {Microcirculation},
year = {2023},
doi = {10.1111/micc.12825}
}
EUVIMED